Liver Cancer - Pipeline Review, H1 2016; New Report Launched

Liver Cancer Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery. 

Liver Cancer pipeline therapeutics constitutes close to 313 molecules. Out of which approximately 265 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 18, 63, 48, 4, 113 and 19 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 7, 1, 29 and 3 molecules, respectively.

The report Liver Cancer – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape of Liver Cancer
• The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
• The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Liver Cancer
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For more information Visit at: http://mrr.cm/JDQ

Related Reports;

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDA

Acute Lung Injury - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDd

Burkholderia Infections - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDP

Progressive Supranuclear Palsy - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDW